



LungHealth
Unified

An integrated approach to lung disease

Why earlier detection, evidence-based therapy, and equitable access matter—now

LungHealth, Unified recognizes **shared risks, pathways, and solutions across lung disease**—with a focus on lung cancer and chronic obstructive pulmonary disease (COPD)—to advance:



Earlier detection



Evidence-based therapy



Equitable access across communities

This integrated approach can close care gaps across the lung health journey—from risk identification to diagnosis, treatment, and long-term management.

Lung Health remains one of the most urgent and addressable public health challenges in the United States, underscoring a persistent and unmet need.



Lung cancer causes

~20%

of all cancer deaths, yet fewer than

1 in 5

eligible adults receive screening.^{1,2}



Early detection saves lives:

Survival is

~65%

when lung cancer is detected early (localized) vs

~30%

overall.¹



COPD affects

~26 M

Americans (diagnosed and undiagnosed), yet less than

~60%

of people with COPD receive expert-recommended therapy.^{3,4}



Rural communities disproportionately bear a higher COPD prevalence and persistently higher lung cancer mortality.^{5,6}

Earlier detection and integrated lung care can improve outcomes and reduce avoidable system burden.

Lung Diseases Don't Exist in Silos—However, Care Systems Often Do



Primary care can be the front door for lung health.⁷



Individuals with COPD have an increased risk of developing lung cancer.⁸



~40% of lung cancer patients have COPD, often undiagnosed.⁹

Connecting COPD and lung cancer pathways can enable smarter, earlier intervention.

CALL TO ACTION

Healthcare Practitioners

Ensure comprehensive lung health assessment at the point of care to routinely assess lung cancer risk and chronic lung disease together.^{7,8}

Evaluate for COPD using appropriate testing to identify undiagnosed COPD when patient presents with symptoms, confirm diagnosis, and guide management.⁹

Optimize expert-recommended COPD treatment to increase adoption of evidence-based therapy to reduce exacerbations.¹²



Health Systems

Integrate lung care pathways to connect COPD and lung cancer pathways across referrals and transitions of care.

Embed lung cancer and COPD prompts to implement EHR-based prompts tied to referral and follow-up.^{10,11}

Guide patient navigation after abnormal findings to ensure timely follow-up and continuity across lung care pathways.¹³

Improving
LungHealth requires
accountable action
across care, policy,
and quality
measures.

Policymakers

Improve access to healthcare and treatment by removing affordability barriers and investing in rural lung health infrastructure and navigation.

Eliminate cost sharing and prior authorization for lung cancer screening and follow-up diagnostics.¹⁴

Ensure biomarker testing coverage to connect patients to the most appropriate treatment option



Therapy & Quality Leaders

Hold health systems accountable through measures and incentives that support early detection and coordinated lung care.

Advance respiratory quality frameworks tied to accurate diagnosis, transitions of care, and expert-recommended therapy adoption.

Expand lung cancer screening eligibility criteria to reflect evolving evidence and high-risk populations.



What AstraZeneca is Doing

Early detection and AI-enabled screening

Supporting the use of advanced analytics and clinical decision tools.

Rural and underserved community engagement

Supporting community-based approaches that expand access.

AstraZeneca works alongside clinicians, health systems, patients, and policymakers to help scale **evidence-based *LungHealth* solutions.**

Early detection and diagnostics support

Partnering on initiatives that support screening uptake and timely diagnostic follow-up.

Policy and systems collaboration

Working to reduce administrative, access, and affordability barriers.



References:

1. National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer. Accessed February 20, 2026. <https://seer.cancer.gov/statfacts/html/lungb.html> 2. American Cancer Society. Latest ACS Lung Cancer Data: Only 1 in 5 Eligible Adults in U.S. Screened for Lung Cancer; 62,000 Lives Over 5 Years Could be Saved if All Eligible Screened. Accessed February 20, 2026. <https://pressroom.cancer.org/2025-lung-cancer-data> 3. Mamary AJ, Stewart JJ, Kinney GL, et al. Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction. *Chronic Obstr Pulm Dis*. 2018;5(3):177-184. Published 2018 Jul 2. doi:10.15326/jcopdf.5.3.2017.0145 4. Raghavan D, Drummond KL, Sanders SA, Kirchner J. Use of implementation science to qualitatively identify implementation determinants of COPD practice guidelines in primary care. *Chron Respir Dis*. 2025;22:14799731251314870. doi:10.1177/147997312513148705. Centers for Disease Control and Prevention. Rural COPD Burden. Accessed February 20, 2026. <https://www.cdc.gov/rural-health/php/public-health-strategy/public-health-strategies-for-copd-burden.html> 6. Centers for Disease Control and Prevention. Cancer Prevention: Rural Policy Brief. Accessed February 20, 2026. <https://www.cdc.gov/rural-health/php/policy-briefs/cancer-policy-brief.html> 7. USPSTF. Lung Cancer: Screening. Accessed February 20, 2026. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening> 8. Zhao G, Li X, Lei S, Zhao H, Zhang H, Li J. Prevalence of lung cancer in chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Front Oncol*. 2022;12:947981. doi:10.3389/fonc.2022.947981 9. Ruparel M, Quaife SL, Dickson JL, et al. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort. *Ann Am Thorac Soc*. 2020;17(7):869-878. doi:10.1513/AnnalsATS.201911-857OC 10. Steinberg MB, Young WJ, Miller Lo EJ, et al. Electronic Health Record Prompt to Improve Lung Cancer Screening in Primary Care. *Am J Prev Med*. 2023;65(5):892-895. doi:10.1016/j.amepre.2023.05.016 11. Wang C, Siff J, Greco PJ, Warren E, Thornton JD, Tarabichi Y. The Impact of an Electronic Health Record Intervention on Spirometry Completion in Patients with Chronic Obstructive Pulmonary Disease. *COPD*. 2022;19(1):142-148. <https://doi.org/10.1080/15412555.2022.2049736> 12. Global Initiative for Chronic Obstructive Lung Disease. 2026 GOLD Report and Pocket Guide. Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report. Accessed February 20, 2026. <https://goldcopd.org/2026-gold-report-and-pocket-guide> 13. Zuniga PVS, Ost DE. Impact of Delays in Lung Cancer Treatment on Survival. *Chest*. 2021;160(5):1934-1958. 14. American Lung Association. State Lung Cancer Screening Coverage Toolkit. Accessed February 20, 2026. <https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/screening-resources/state-lung-cancer-screening>